{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:54:41Z","timestamp":1793912081944,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10549-026-08021-4","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:08:41Z","timestamp":1783696121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer"],"prefix":"10.1007","volume":"218","author":[{"given":"Adhar","family":"Amritt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhilash","family":"Dagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrija","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaswin","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta","family":"Hazarika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Datt","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra K.","family":"Meena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoutishman","family":"Saikia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4228-5211","authenticated-orcid":false,"given":"Supriya","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"8021_CR1","doi-asserted-by":"publisher","unstructured":"Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13(1):8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8","DOI":"10.1200\/JCO.1995.13.1.8"},{"key":"8021_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.radonc.2018.11.022","volume":"131","author":"MT Milano","year":"2019","unstructured":"Milano MT, Katz AW, Zhang H, Huggins CF, Aujla KS, Okunieff P (2019) Oligometastatic breast cancer treated with hypofractionated stereotactic radiotherapy: Some patients survive longer than a decade. Radiother Oncol 131:45\u201351. https:\/\/doi.org\/10.1016\/j.radonc.2018.11.022","journal-title":"Radiother Oncol"},{"key":"8021_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.11.047","author":"A Dagar","year":"2026","unstructured":"Dagar A, Ghosh A, Singhal A, Kumar A, Sharma J, Sharma A et al (2026) A Study of Curative Approach Treatment Along With Metastasis-Directed Stereotactic Body Radiation Therapy in Bone-Only Oligometastatic Breast Cancer. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.11.047","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"8021_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30718-1","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, Desouza NM et al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Rev Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1","journal-title":"Rev Lancet Oncol"},{"issue":"17","key":"8021_CR5","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC et al (2009) Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15(17):5379\u20135388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0265","journal-title":"Clin Cancer Res"},{"key":"8021_CR6","doi-asserted-by":"publisher","unstructured":"Daguenet E, Louati S, Wozny AS, Vial N, Gras M, Guy JB, et al (2020) Radiation-induced bystander and abscopal effects: important lessons from preclinical models. Br J Cancer 123(3):339-348. https:\/\/doi.org\/10.1038\/s41416-020-0942-3","DOI":"10.1038\/s41416-020-0942-3"},{"key":"8021_CR7","doi-asserted-by":"publisher","unstructured":"Timmerman R (2022) A story of hypofractionation and the table on the wall. Int J Radiat Oncol Biol Phys 112(1):4\u201321. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.09.027","DOI":"10.1016\/j.ijrobp.2021.09.027"},{"issue":"15","key":"8021_CR8","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/S1470-2045(15)00199-0","volume":"16","author":"E Chow","year":"2015","unstructured":"Chow E, Meyer RM, Ding K, Nabid A, Chabot P, Wong P et al (2015) Dexamethasone in the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases: A double-blind, randomised placebo-controlled, phase 3 trial. Lancet Oncol 16(15):1463\u20131472. https:\/\/doi.org\/10.1016\/S1470-2045(15)00199-0","journal-title":"Lancet Oncol"},{"key":"8021_CR9","doi-asserted-by":"publisher","unstructured":"Kucharczyk MJ, Parpia S, Walker-Dilks C, Banfield L, Swaminath A (2017) Ablative therapies in metastatic breast cancer: a systematic review. Breast Cancer Res Treat 164(1):13\u201325. https:\/\/doi.org\/10.1007\/s10549-017-4228-2","DOI":"10.1007\/s10549-017-4228-2"},{"key":"8021_CR10","doi-asserted-by":"publisher","unstructured":"Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, et al (2022) NRG-BR002: A phase IIR\/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and\/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). J Clin Oncol 40. https:\/\/doi.org\/10.1158\/1538-7445.SABCS15-OT3-03-04","DOI":"10.1158\/1538-7445.SABCS15-OT3-03-04"},{"issue":"11","key":"8021_CR11","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1245\/s10434-018-6494-6","volume":"25","author":"A Soran","year":"2018","unstructured":"Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A et al (2018) Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01. Ann Surg Oncol 25(11):3141\u20133149. https:\/\/doi.org\/10.1245\/s10434-018-6494-6","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"8021_CR12","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","volume":"16","author":"R Badwe","year":"2015","unstructured":"Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S et al (2015) Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial. Lancet Oncol 16(13):1380\u20131388. https:\/\/doi.org\/10.1016\/S1470-2045(15)00135-7","journal-title":"Lancet Oncol"},{"issue":"1","key":"8021_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.radonc.2017.08.032","volume":"126","author":"M Trovo","year":"2018","unstructured":"Trovo M, Furlan C, Polesel J, Fiorica F, Arcangeli S, Giaj-Levra N et al (2018) Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trial. Radiother Oncol 126(1):177\u2013180. https:\/\/doi.org\/10.1016\/j.radonc.2017.08.032","journal-title":"Radiother Oncol"},{"key":"8021_CR14","doi-asserted-by":"publisher","unstructured":"Lemoine P, Bruand M, Kammerer E, Bogart E, Comte P, Royer P, et al (2021) Stereotactic body radiation therapy for oligometastatic breast cancer: a retrospective multicenter study. Front Oncol 11. https:\/\/doi.org\/10.3389\/fonc.2021.736690","DOI":"10.3389\/fonc.2021.736690"},{"issue":"10162","key":"8021_CR15","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353\u20132366. https:\/\/doi.org\/10.1016\/S0140-6736(18)32486-3","journal-title":"Lancet"},{"key":"8021_CR16","doi-asserted-by":"publisher","unstructured":"Burkon P, Selingerova I, Slavik M, Pospisil P, Bobek L, Kominek L et al (2021) Stereotactic body radiotherapy for lymph node oligometastases: real-world evidence from 90 consecutive patients. Front Oncol 10. https:\/\/doi.org\/10.3389\/fonc.2020.616494","DOI":"10.3389\/fonc.2020.616494"},{"key":"8021_CR17","doi-asserted-by":"publisher","unstructured":"Guti\u00e9rrez E, S\u00e1nchez I, D\u00edaz O, Valles A, Balderrama R, Fuentes J, et al (2021) Current evidence for stereotactic body radiotherapy in lung metastases. Curr Oncol 28(4):2560\u20132578. https:\/\/doi.org\/10.3390\/curroncol28040233","DOI":"10.3390\/curroncol28040233"},{"issue":"3","key":"8021_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00066-021-01845-7","volume":"198","author":"E Oymak","year":"2022","unstructured":"Oymak E, Guler OC, Onal C (2022) Significance of liver metastasis volume in breast cancer patients treated with stereotactic body radiotherapy. Strahlenther Onkol 198(3):247\u2013253. https:\/\/doi.org\/10.1007\/s00066-021-01845-7","journal-title":"Strahlenther Onkol"},{"key":"8021_CR19","doi-asserted-by":"publisher","unstructured":"Franzese C, Louie AV, Kotecha R, Zhang Z, Guckenberger M, Kim MS, et al (2024) Stereotactic body radiation therapy for liver metastases: systematic review and meta-analysis with International Stereotactic Radiosurgery Society (ISRS) practice guidelines. Pract Radiat Oncol. https:\/\/doi.org\/10.1016\/j.prro.2024.09.011","DOI":"10.1016\/j.prro.2024.09.011"},{"issue":"20","key":"8021_CR20","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1200\/JCO.2007.14.2471","volume":"26","author":"CK Anders","year":"2008","unstructured":"Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26(20):3324\u20133330. https:\/\/doi.org\/10.1200\/JCO.2007.14.2471","journal-title":"J Clin Oncol"},{"issue":"12","key":"8021_CR21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer \u2606. Ann Oncol 32(12):1475\u20131495. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019","journal-title":"Ann Oncol"},{"key":"8021_CR22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.radonc.2021.09.031","volume":"164","author":"GA Viani","year":"2021","unstructured":"Viani GA, Gouveia AG, Louie AV, Korzeniowski M, Pavoni JF, Hamamura AC et al (2021) Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis: SBRT for breast cancer oligometastases. Radiother Oncol 164:245\u2013250. https:\/\/doi.org\/10.1016\/j.radonc.2021.09.031","journal-title":"Radiother Oncol"},{"issue":"2","key":"8021_CR23","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.3390\/curroncol30020108","volume":"30","author":"D Leblanc","year":"2023","unstructured":"Leblanc D, Cantin G, Desnoyers A, Dufresne J, Masucci GL, Panet-Raymond V et al (2023) Management of Oligometastatic Breast Cancer: An Expert Committee\u2019s Opinion. Curr Oncol 30(2):1416\u20131425. https:\/\/doi.org\/10.3390\/curroncol30020108","journal-title":"Curr Oncol"},{"issue":"1","key":"8021_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.breast.2013.10.007","volume":"23","author":"U G\u00fcth","year":"2014","unstructured":"G\u00fcth U, Magaton I, Huang DJ, Fisher R, Sch\u00f6tzau A, Vetter M (2014) Primary and secondary distant metastatic breast cancer: Two sides of the same coin. Breast 23(1):26\u201332. https:\/\/doi.org\/10.1016\/j.breast.2013.10.007","journal-title":"Breast"},{"issue":"11","key":"8021_CR25","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.clon.2023.08.006","volume":"35","author":"SK Nagpal","year":"2023","unstructured":"Nagpal SK, Khabra K, Ross G, Kirby AM (2023) Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit? Clin Oncol 35(11):736\u2013743. https:\/\/doi.org\/10.1016\/j.clon.2023.08.006","journal-title":"Clin Oncol"},{"issue":"10","key":"8021_CR26","doi-asserted-by":"publisher","first-page":"7858","DOI":"10.3390\/curroncol29100621","volume":"29","author":"D Franceschini","year":"2022","unstructured":"Franceschini D, Comito T, Di Gallo A, Vernier V, Marzo MA, Di Cristina L et al (2022) Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial. Curr Oncol 29(10):7858\u20137867. https:\/\/doi.org\/10.3390\/curroncol29100621","journal-title":"Curr Oncol"},{"key":"8021_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ctro.2021.03.012","volume":"28","author":"D Krug","year":"2021","unstructured":"Krug D, Vonthein R, Illen A, Olbrich D, Barkhausen J, Richter J et al (2021) Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA). Clin Transl Radiat Oncol 28:90\u201396. https:\/\/doi.org\/10.1016\/j.ctro.2021.03.012","journal-title":"Clin Transl Radiat Oncol"},{"key":"8021_CR28","doi-asserted-by":"publisher","unstructured":"Sasaki K, Ishiba T, Nishibuchi I, Hara F, Sekino Y, Machida R, et al (2026) A randomized controlled trial of metastasis-directed therapy for oligometastases in breast cancer: OLIGAMI trial (JCOG2110). Jpn J Clin Oncol 30. https:\/\/doi.org\/10.1093\/jjco\/hyag019","DOI":"10.1093\/jjco\/hyag019"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08021-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08021-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08021-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:02:55Z","timestamp":1785445375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08021-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8021"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08021-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"IRB approval-AIIMSA 5045\/07.11.2025, RP-57\/2025.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that participant consent was received.","order":2,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"9"}}